Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/105329
DC FieldValueLanguage
dc.contributor.authorBhia, Mohammed-
dc.contributor.authorMotallebi, Mahzad-
dc.contributor.authorAbadi, Banafshe-
dc.contributor.authorZarepour, Atefeh-
dc.contributor.authorSilva, Miguel Pereira da-
dc.contributor.authorSaremnejad, Farinaz-
dc.contributor.authorSantos, Ana Cláudia-
dc.contributor.authorZarrabi, Ali-
dc.contributor.authorMelero, Ana-
dc.contributor.authorJafari, Seid Mahdi-
dc.contributor.authorShakibaei, Mehdi-
dc.date.accessioned2023-02-17T10:07:13Z-
dc.date.available2023-02-17T10:07:13Z-
dc.date.issued2021-02-23-
dc.identifier.issn1999-4923pt
dc.identifier.urihttps://hdl.handle.net/10316/105329-
dc.description.abstractNaringenin (NRG) is a polyphenolic phytochemical belonging to the class of flavanones and is widely distributed in citrus fruits and some other fruits such as bergamot, tomatoes, cocoa, and cherries. NRG presents several interesting pharmacological properties, such as anti-cancer, anti-oxidant, and anti-inflammatory activities. However, the therapeutic potential of NRG is hampered due to its hydrophobic nature, which leads to poor bioavailability. Here, we review a wide range of nanocarriers that have been used as delivery systems for NRG, including polymeric nanoparticles, micelles, liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), nanosuspensions, and nanoemulsions. These nanomedicine formulations of NRG have been applied as a potential treatment for several diseases, using a wide range of in vitro, ex vivo, and in vivo models and different routes of administration. From this review, it can be concluded that NRG is a potential therapeutic option for the treatment of various diseases such as cancer, neurological disorders, liver diseases, ocular disorders, inflammatory diseases, skin diseases, and diabetes when formulated in the appropriate nanocarriers.pt
dc.language.isoengpt
dc.publisherMDPIpt
dc.relationUniversity of Valencia and the Valencian Government (grant numbers UV-19-INV_AE19 and GV2015-054)pt
dc.rightsopenAccesspt
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt
dc.subjectnaringeninpt
dc.subjectnutraceuticalspt
dc.subjectantioxidantspt
dc.subjectnatural productspt
dc.subjectnanoparticlespt
dc.subjectdrug deliverypt
dc.subjectnanomedicinept
dc.subjectbioavailabilitypt
dc.subjectflavonoidpt
dc.titleNaringenin Nano-Delivery Systems and Their Therapeutic Applicationspt
dc.typearticle-
degois.publication.firstPage291pt
degois.publication.issue2pt
degois.publication.titlePharmaceuticspt
dc.peerreviewedyespt
dc.identifier.doi10.3390/pharmaceutics13020291pt
degois.publication.volume13pt
dc.date.embargo2021-02-23*
uc.date.periodoEmbargo0pt
item.grantfulltextopen-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.openairetypearticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextCom Texto completo-
crisitem.author.orcid0000-0003-2710-6000-
Appears in Collections:FFUC- Artigos em Revistas Internacionais
Files in This Item:
Show simple item record

SCOPUSTM   
Citations

90
checked on May 6, 2024

WEB OF SCIENCETM
Citations

78
checked on May 2, 2024

Page view(s)

38
checked on May 14, 2024

Download(s)

22
checked on May 14, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons